how were glp 1 agonists discovered GLP-1 medications are not approved by the Food and Drug Administration to treat polyendocrine metabolic ovarian syndrome (PMOS), the condition renamed from polycystic ovary syndrome in 2026. Because the use is off-label glp-1 medications names list of

Kornblau SM, Konopleva M, Andreeff M

AOD9604 vs Intact hGH in Obesity Models A direct head-to-head comparison of AOD9604 and intact hGH in obese and lean mice confirmed that both compounds significantly reduced body weight gain in obese animals through increased fat oxidation and lipolysis stimulation but that AOD9604 achieved this without the hGH receptor binding, IGF-1 stimulation, hyperglycaemia, or reduced insulin secretion associated with full-length hGH treatment

Eliminating endocrine disruptors from your environment, including xenoestrogens found in plastics, personal care products, and processed foods

The study found that tissue glycine levels in many individuals fall below the Michaelis constant for the enzyme glutathione synthase, meaning the enzyme cannot operate at full capacity

Intravenous and intranasal Parkinsons disease trials did not demonstrate superiority over placebo